Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlycoNexROCO:4168 57 PB Ratio is 2.53 as of Jul. 31, 2026, which is 33% above its 10-year median of 1.90. GuruFocus rates ROCO:4168 with a GF Score™ of 57/100 and a GF Value™ of NT$76.21 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, GlycoNex ranks better than 52.36% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-31), GlycoNex's share price is NT$22.05. GlycoNex's Book Value per Share for the quarter that ended in Dec. 2025 was NT$8.73. Hence, GlycoNex's PB Ratio of today is 2.53.
The historical rank and industry rank for GlycoNex's PB Ratio or its related term are showing as below:
ROCO:4168'
s PB Ratio Range Over the Past 10 Years
Min: 0.66 Med: 1.9 Max: 3.31
Current: 2.53
During the past 13 years, GlycoNex's highest PB Ratio was 3.31. The lowest was 0.66. And the median was 1.90.
ROCO:4168's PB Ratio is ranked better than 52.36% of 1228
companies
in the Biotechnology industry
Industry Median: 2.705
vs ROCO:4168: 2.53
During the past 12 months, GlycoNex's average Book Value Per Share Growth Rate was -9.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GlycoNex was 82.70% per year. The lowest was -13.40% per year. And the median was -8.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GlycoNex PB Ratio Related Terms
GlycoNex PB Ratio Historical Data
* Premium members only.
The historical data trend for GlycoNex's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, GlycoNex's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's PB Ratio distribution charts can be found below:
* The bar in red indicates where GlycoNex's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
GlycoNex's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GlycoNex (ROCO:4168) has a PB Ratio of 2.53 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlycoNex and its competitors. This is 33% above median its historical median of 1.90. Over the past decade, GlycoNex's PB Ratio has ranged from 0.66 to 3.31. According to the industry distribution chart, GlycoNex ranks #585 out of 1228 companies in the Biotechnology industry, placing it in the top 47.6%.
Is GlycoNex's PB Ratio too high?
GlycoNex's current PB Ratio of 2.53 is 33% above median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 3.31. The Biotechnology industry median PB Ratio is 2.71. GlycoNex's value of 2.53 is 6.5% below this industry median. Based on the distribution chart, GlycoNex ranks #585 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GlycoNex has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #585 out of 1228 companies for PB Ratio. This puts GlycoNex in the upper half of its industry. The industry median PB Ratio is 2.71. GlycoNex's value of 2.53 is 6.5% below this benchmark. Historically, GlycoNex's own PB Ratio has ranged from 0.66 to 3.31 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 2.71, GlycoNex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.71, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlycoNex's current PB Ratio of 2.53 is 6.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlycoNex and its competitors. For the Biotechnology industry, the median PB Ratio is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlycoNex's current PB Ratio is 2.53, which is 33% above median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$76.21, compared to a current price of NT$22.05 — trading 71.1% below its estimated fair value. The current PB Ratio is 2.53, which is 33% above median its 10-year median of 1.90 and 6.5% below the Biotechnology industry median of 2.71. GlycoNex's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current PB Ratio is 2.53 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$22.05 is trading 71.1% below its estimated GF Value™ of NT$76.21.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
PB Ratio: 2.53 (33% above median its 10-year median of 1.90)
GF Value™: NT$76.21 vs. price of NT$22.05 (71.1% below fair value)
Industry Position: 6.5% below the Biotechnology median (#585 of 1228)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
57GF Score
Get the complete analysis for ROCO:4168
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
